Marker Therapeutics ( (MRKR) ) has released its Q4 earnings. Here is a breakdown of the information Marker Therapeutics presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Marker Therapeutics, Inc. is a Houston-based clinical-stage immuno-oncology company that develops next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors.
In its latest earnings report for the year ending December 31, 2024, Marker Therapeutics highlighted significant advancements in its lead program, MT-601, which is being investigated for its efficacy in patients with refractory lymphomas. The company also secured substantial non-dilutive funding to support its clinical programs.
The company’s Phase 1 APOLLO study of MT-601 showed promising results, with a 78% objective response rate in patients with relapsed lymphoma. Financially, Marker strengthened its position with over $13 million in non-dilutive funding from CPRIT and NIH, and a $16.1 million private placement. Despite reporting a net loss of $10.7 million for 2024, the company’s cash position improved to $19.2 million, expected to fund operations into the first quarter of 2026.
Looking ahead, Marker Therapeutics plans to continue its focus on advancing MT-601 and launching clinical programs for MT-601 in pancreatic cancer and MT-401-OTS in acute myeloid leukemia. The company remains committed to preserving cash and executing its strategic initiatives effectively.